REDWOOD CITY, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology therapeutics, will announce financial results for the quarter ended June 30, 2015 on Monday, August 10, 2015 after the close of U.S.-based financial markets. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review the results beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing (855) 420-0692 for domestic callers and (484) 756-4194 using the conference ID# 5922193. Please note that slides accompanying management's presentation will be posted to the OncoMed website on the Events page within the Investor Relations section.
The press release and webcast of the conference call will be accessible through a link in the Investor Relations section of the OncoMed website:
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website:
|Media & Investors|
|Senior Director, Investor Relations and Corporate Communications|